Monozyme India Ltd vs APOLLO HOSPITALS ENTER. L

A side-by-side comparison of Monozyme India Ltd (522199) and APOLLO HOSPITALS ENTER. L (APOLLOHOSP) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, APOLLO HOSPITALS ENTER. L leads 522199 vs APOLLOHOSP on 8 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability13
  • Growth· not comparable
  • Size & financial health13

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

0.00
P/E ratio
64.15
0.00
P/B ratio
12.55
0.00%
Dividend yield
0.23%
₹0.71
EPS
₹135.04

Profitability

APOLLOHOSP takes 3/4

How efficiently each company turns capital and sales into profit. Higher is better.

-42.80%
Return on equity
22.10%
-5.08%
Return on capital
18.00%
23.01%
EBITDA margin
15.00%
3.53%
Net margin
7.94%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

Revenue CAGR (3Y) even
14.94%
Profit CAGR (3Y) even
33.39%

Size & financial health

APOLLOHOSP takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹0 Cr
Market cap
₹1.25L Cr
₹49 Cr
Revenue
₹25,228 Cr
₹2 Cr
Net profit
₹2,003 Cr
0.00
Debt / equity
0.32
Monozyme India Ltd
  • + ["Company has reduced debt."]
  • ["Company has low interest coverage ratio.", "Company has a low return on equity of -24.5% over last 3 years.", "Company has high debtors of 50,127 days.", "Working capital days have increased from 15,794 days to 46,842 days"]
APOLLO HOSPITALS ENTER. L
  • + ["Company has delivered good profit growth of 76.2% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 17.7%"]
  • ["Stock is trading at 13.4 times its book value", "Company might be capitalizing the interest cost"]
Monozyme India Ltd full analysis APOLLO HOSPITALS ENTER. L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.